Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 6 of 15
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
NCT05873192
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
University of Rochester
NCT05530655
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
NCT07145177
UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning
University of Florida
NCT06465966
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
M.D. Anderson Cancer Center
NCT05454488
Hypofractionated WPPT With HDR Boost
Abramson Cancer Center at Penn Medicine
NCT06591819
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
NCT06972628
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05079698
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05751941
High Intensity Focused Ultrasound in Prostate Cancer
University of Florida
NCT06402357
PET/CT Characterization of Treatment Resistance
University of Wisconsin, Madison
NCT05647564
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
University of Texas Southwestern Medical Center
NCT06353321
Circulating Tumor DNA in High Risk Localized Prostate Cancer
University of Pittsburgh
NCT07222436
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
NCT04887935
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
National Cancer Institute (NCI)
NCT04808427
Periprostatic Neurolysis in Prostate Cancer
University of Texas Southwestern Medical Center
NCT07100847
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
University of Maryland, Baltimore
NCT04698564
Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)
University of Miami
NCT06487507
Exercise in Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06165302
TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer
Urological Research Network
NCT05698576
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03861676
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
SURGE Therapeutics
NCT06450106
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
University of Maryland, Baltimore
NCT04486755
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04167969
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Dana-Farber Cancer Institute
NCT05899361
Agriculture Health Study
National Cancer Institute (NCI)
NCT00352924
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00579514
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Memorial Sloan Kettering Cancer Center
NCT00578240
Aberrant Gene Expression Prostate Carcinoma
Lahey Clinic
NCT00868803
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
University of California, San Francisco
NCT00769223
Trial of Modifications to Radical Prostatectomy
Memorial Sloan Kettering Cancer Center
NCT01407263
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
University of Florida
NCT03561220
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
Nanostics
NCT03957252
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
NCT01368588
Prostate Cancer Prospective Cohort
Washington University School of Medicine
NCT00937586
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
NCT00567580
Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James
Ohio State University Comprehensive Cancer Center
NCT01643954
PSMA PET Imaging of Recurrent Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT03204123
Social Risk Factors and Discrimination in Cancer Survivorship
Medstar Health Research Institute
NCT05301114
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
University of Sydney
NCT04136353
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
NCT02319837
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Aragon Pharmaceuticals
NCT02489318
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
Memorial Sloan Kettering Cancer Center
NCT02917798
Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
City of Hope Medical Center
NCT00977457
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
AstraZeneca
NCT05348577
Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men
Jonsson Comprehensive Cancer Center
NCT00761124
Phase II Laser Focal Therapy of Prostate Cancer
HALO Diagnostics
NCT02243033
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America
NCT05467176
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
Bayer
NCT04122976
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.